Last reviewed · How we verify
High-dose dexmedetomidine
High-dose dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
High-dose dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation in intensive care unit patients, Perioperative sedation and analgesia, Sedation during mechanical ventilation.
At a glance
| Generic name | High-dose dexmedetomidine |
|---|---|
| Also known as | Yisi |
| Sponsor | Tang-Du Hospital |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds to alpha-2 adrenergic receptors with high selectivity, leading to inhibition of norepinephrine release and reduced neuronal firing in key brain regions. At high doses, it produces profound sedation and analgesia while maintaining airway reflexes. The drug is commonly used in intensive care and perioperative settings for sedation and analgesia in critically ill or anesthetized patients.
Approved indications
- Sedation in intensive care unit patients
- Perioperative sedation and analgesia
- Sedation during mechanical ventilation
Common side effects
- Hypotension
- Bradycardia
- Hypertension (initial)
- Dry mouth
- Rebound hypertension on withdrawal
Key clinical trials
- Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery (PHASE2)
- Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging (PHASE4)
- Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering (PHASE3)
- Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle (EARLY_PHASE1)
- The Role of the LC-NA System in Experimental Sleep Fragmentation (PHASE1)
- Hemodynamic Effects of Fentanyl Vs Dexmedetomidine in Spine Surgery (PHASE4)
- Comparison of Caudal Block and Sacral Erector Spinae Plane Block With Dexmedetomidine in Pediatric Penile Hypospadias Repair (PHASE3)
- The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose dexmedetomidine CI brief — competitive landscape report
- High-dose dexmedetomidine updates RSS · CI watch RSS
- Tang-Du Hospital portfolio CI